# A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer

> **NCT03472053** · PHASE2 · COMPLETED · sponsor: **BioMarck Pharmaceuticals, Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Non Small Cell Lung Cancer Stage IIIB

## Interventions

- **DRUG:** BIO-11006 plus standard of care
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT03472053
- **Lead sponsor:** BioMarck Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-01
- **Primary completion:** 2019-12-30
- **Final completion:** 2019-12-30
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03472053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03472053, "A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03472053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*